- Treatment of atopic dermatitis (AD) with dupilumab (Dupixent) was associated with a higher real-world incidence of conjunctivitis and eosinophilia than that reported in clinical studies.
- Efficacy was similar to that reported in clinical trials.
Why this matters
- Real-world studies are essential for validating results from clinical trials, which only represent a select population.
- 16.6% of patients achieved ≥75% improvement in Scoring Atopic Dermatitis (SCORAD75), and 48.8% achieved ≥75% improvement in Eczema Area and Severity Index (EASI75).
- Median SCORAD and EASI scores were lower at 3 months compared with baseline (25 vs 56 [P−9] and 4.1 vs 17.9 [P−9], respectively).
- 38.2% of patients experienced conjunctivitis during follow-up compared with 8% in a meta-analysis based on trials.
- 56.5% of patients experienced eosinophilia during follow-up (vs 33.7% at baseline; P−6) compared with
- Development of conjunctivitis was associated with a medical history of allergic conjunctivitis (P<.003 whereas eosinophilia during follow-up was associated with at baseline>−9), asthma (P<.001 allergic rhinitis and food allergy>
- 11.2% of patients discontinued because of an adverse event.
- Retrospective study of 241 patients from 29 centers with dupilumab-treated AD.
- Funding: None.
- No control patient group.